Getu Zhaori
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Getu Zhaori has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Chunyan Liu
Editorial Office Pediatric Investigation, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health Beijing China
2 shared publicationsLu Lu
Editorial Office Pediatric Investigation, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health Beijing China
2 shared publicationsYongli Guo
Editorial Office Pediatric Investigation, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health Beijing China
2 shared publicationsShujing Han
Editorial Office Pediatric Investigation, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health Beijing China
1 shared publication
Latest Publications
- Open Access
- 24 January 2024
- Published by Wiley in Pediatric Investigation
- Vol. 8 (1) , 7-11
Importance of sample size determination for randomized controlled clinical trials for coronavirus disease 2019 antiviral therapies
For the calculation of sample size for a randomized controlled clinical trial, choosing a proper, medium clinically meaningful difference in the size of the effect of the test and control interventions is important for avoiding too small or too large sample sizes.
- 24 January 2024
- Published by Wiley in Pediatric Investigation
- Vol. 8 (1) , 7-11
Open AccessImportance of sample size determination for randomized controlled clinical trials for coronavirus disease 2019 antiviral therapies
For the calculation of sample size for a randomized controlled clinical trial, choosing a proper, medium clinically meaningful difference in the size of the effect of the test and control interventions is important for avoiding too small or too large sample sizes.
- Open Access
- 10 May 2023
- Published by Wiley in Pediatric Investigation
- Vol. 7 (2) , 144-146
Nirsevimab brings breakthrough in the prevention of respiratory syncytial virus infection in infants – Importance of design
- 10 May 2023
- Published by Wiley in Pediatric Investigation
- Vol. 7 (2) , 144-146
Open AccessNirsevimab brings breakthrough in the prevention of respiratory syncytial virus infection in infants – Importance of design
- Open Access
- 9 May 2023
- Published by Wiley in Pediatric Investigation
- Vol. 7 (2) , 147-149
A new column in this journal – Forum on Clinical Investigation
- 9 May 2023
- Published by Wiley in Pediatric Investigation
- Vol. 7 (2) , 147-149
Open AccessA new column in this journal – Forum on Clinical Investigation
- Open Access
- 9 January 2023
- Published by Wiley in Pediatric Investigation
- Vol. 7 (1) , 1-5
Better design leads to better results – Importance of virological outcome design in clinical trials for antiviral treatment of coronavirus disease 2019
- 9 January 2023
- Published by Wiley in Pediatric Investigation
- Vol. 7 (1) , 1-5
Open AccessBetter design leads to better results – Importance of virological outcome design in clinical trials for antiviral treatment of coronavirus disease 2019
- Open Access
- 11 July 2022
- Published by Wiley in Pediatric Investigation
- Vol. 6 (3) , 211-218
Severe acute hepatitis of unknown causes in children – Current findings, questions, opinions, and recommendations, a mini‐review
Since October 2021 in Alabama, the United States, and March 2022 in central Scotland, the United Kingdom, the number of cases of severe acute hepatitis of unknown etiology/causes in children was found to increase, and the total number of cases has reached 920 worldwide by June 22 this year, 45 cases (5%) required liver transplantation, and 18 cases (2%) died according to World Health Organization (WHO). To understand the basic characteristics of this disease/syndrome, a literature search was performed at PubMed, websites of WHO, UK Health Security Agency, and US and European Centers for Disease Control and Prevention, and more than 20 reports were enrolled as references for this review. The main clinical manifestations are anorexia, vomiting, fatigue, jaundice, and so forth. Most of the cases seemed to have a self‐limited course of the disease, about 6% of cases may develop life‐threatening acute liver failure. The disease seems to be transmissible from person to person. Human adenovirus was detected in up to 75% of cases, but this virus seems not to be the only and major etiologic agent, other cofactors probably are involved. Researchers proposed many hypotheses concerning the etiology and pathogenesis, and many important works and studies are ongoing. This mini‐review is aimed at summarizing, reviewing, and further understanding the characteristics of the disease, raising some clinically relevant questions, and trying to discuss some questions that may be related to the treatment of the disease for consideration.
- 11 July 2022
- Published by Wiley in Pediatric Investigation
- Vol. 6 (3) , 211-218
Open AccessSevere acute hepatitis of unknown causes in children – Current findings, questions, opinions, and recommendations, a mini‐review
Since October 2021 in Alabama, the United States, and March 2022 in central Scotland, the United Kingdom, the number of cases of severe acute hepatitis of unknown etiology/causes in children was found to increase, and the total number of cases has reached 920 worldwide by June 22 this year, 45 cases (5%) required liver transplantation, and 18 cases (2%) died according to World Health Organization (WHO). To understand the basic characteristics of this disease/syndrome, a literature search was performed at PubMed, websites of WHO, UK Health Security Agency, and US and European Centers for Disease Control and Prevention, and more than 20 reports were enrolled as references for this review. The main clinical manifestations are anorexia, vomiting, fatigue, jaundice, and so forth. Most of the cases seemed to have a self‐limited course of the disease, about 6% of cases may develop life‐threatening acute liver failure. The disease seems to be transmissible from person to person. Human adenovirus was detected in up to 75% of cases, but this virus seems not to be the only and major etiologic agent, other cofactors probably are involved. Researchers proposed many hypotheses concerning the etiology and pathogenesis, and many important works and studies are ongoing. This mini‐review is aimed at summarizing, reviewing, and further understanding the characteristics of the disease, raising some clinically relevant questions, and trying to discuss some questions that may be related to the treatment of the disease for consideration.
- Open Access
- 28 December 2020
- Published by Wiley in Pediatric Investigation
- Vol. 4 (4) , 263-274
Progresses in clinical studies on antiviral therapies for COVID‐19—Experience and lessons in design of clinical trials
Antiviral therapy with antiviral agents is a very important component of treatment for the 2019 novel coronavirus disease (COVID‐19) caused by the severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2). It is important to clarify how to evaluate efficacy and safety of antiviral agents in treatment of COVID‐19 during the pandemic of this disease. We need to answer the following questions: do we still need to use rigorously designed randomized controlled clinical trials (RCTs)? Or, will it be enough if we use loosened criteria, observational studies or even retrospective case series and case reports? The answer is “No, we still need to use the strictly designed preferably blinded multicenter RCTs to evaluate the antiviral agents.” In this article, we reviewed almost all the RCT reports on monotherapies and combined therapies with antiviral agents for COVID‐19, and found that among the reports on monotherapies, only remdesivir, and among combined antiviral agents, only the combined regimen with interferon‐β1b, lopinavir‐ritonavir and ribavirin were effective and safe based on evidences from RCTs. The results of five RCTs for chloroquine or hydroxychloroquine consistently showed that they were ineffective and unsafe in the treatment of COVID‐19, especially at larger doses. Many aspects in the design of the clinical trials may be related to success or failure of a trial and the relevant factors need to be analyzed, discussed and emphasized from the specific requirements and considerations of antiviral therapies. We hope such discussions be of certain use in designing clinical trials for pediatric antiviral therapies.
- 28 December 2020
- Published by Wiley in Pediatric Investigation
- Vol. 4 (4) , 263-274
Open AccessProgresses in clinical studies on antiviral therapies for COVID‐19—Experience and lessons in design of clinical trials
Antiviral therapy with antiviral agents is a very important component of treatment for the 2019 novel coronavirus disease (COVID‐19) caused by the severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2). It is important to clarify how to evaluate efficacy and safety of antiviral agents in treatment of COVID‐19 during the pandemic of this disease. We need to answer the following questions: do we still need to use rigorously designed randomized controlled clinical trials (RCTs)? Or, will it be enough if we use loosened criteria, observational studies or even retrospective case series and case reports? The answer is “No, we still need to use the strictly designed preferably blinded multicenter RCTs to evaluate the antiviral agents.” In this article, we reviewed almost all the RCT reports on monotherapies and combined therapies with antiviral agents for COVID‐19, and found that among the reports on monotherapies, only remdesivir, and among combined antiviral agents, only the combined regimen with interferon‐β1b, lopinavir‐ritonavir and ribavirin were effective and safe based on evidences from RCTs. The results of five RCTs for chloroquine or hydroxychloroquine consistently showed that they were ineffective and unsafe in the treatment of COVID‐19, especially at larger doses. Many aspects in the design of the clinical trials may be related to success or failure of a trial and the relevant factors need to be analyzed, discussed and emphasized from the specific requirements and considerations of antiviral therapies. We hope such discussions be of certain use in designing clinical trials for pediatric antiviral therapies.
- Open Access
- 24 June 2020
- Published by Wiley in Pediatric Investigation
- Vol. 4 (2) , 148-149
Further standardization and safety issues for antiviral therapy during pregnancy
- 24 June 2020
- Published by Wiley in Pediatric Investigation
- Vol. 4 (2) , 148-149
Open AccessFurther standardization and safety issues for antiviral therapy during pregnancy
- Open Access
- 1 June 2020
- Published by Wiley in Pediatric Investigation
- Vol. 4 (2) , 73-76
Professor Robert Freedman and his contributions to psychiatric research
- 1 June 2020
- Published by Wiley in Pediatric Investigation
- Vol. 4 (2) , 73-76
Open AccessProfessor Robert Freedman and his contributions to psychiatric research
- Open Access
- 1 June 2020
- Published by Wiley in Pediatric Investigation
- Vol. 4 (2) , 84-85
Smoke evacuation, is it important for prevention of COVID-19?
- 1 June 2020
- Published by Wiley in Pediatric Investigation
- Vol. 4 (2) , 84-85
Open AccessSmoke evacuation, is it important for prevention of COVID-19?
- Open Access
- 1 September 2018
- Published by Wiley in Pediatric Investigation
- Vol. 2 (3) , 164-165
Old problem may have new solution
- 1 September 2018
- Published by Wiley in Pediatric Investigation
- Vol. 2 (3) , 164-165
Open AccessOld problem may have new solution